🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to the results! But is upfront surgery better than either neoadjuvant option? 😉 #NORPACTtrial Knut Jørgen Labori Ernesto Sparrelid Kjetil Søreide Kristoffer Lassen ascopubs.org/doi/abs/10.120…

Gem-cis with or without HAIP chemotherapy for unresectable liver-confined intrahepatic #cholangio. 3-yr OS; 3% versus 34% favoring HAIP adjusted HR: 0.27 (0.19-0.39) PDF; link.springer.com/content/pdf/10… Flavio G Rocha, MD, FACS, FSSO Michael D’Angelica Timothy M. Pawlik Skye C. Mayo, MD, MPH Cholangiocarcinoma Foundation Jesus Bañales

It’s a pleasure and a privilege to have dr. Wuletaw Chane visiting from St. Paul’s hospital in Addis Ababa, Ethiopia. Here with Sheraz Yaqub . Together with dr. Wubetie Yerdaw Molla (surgeon) and dr. Samrawit Tessew Mekuria (anaesthesia) we are discussing HPB-collaboration.

PREOPANC-2 - neoadj FFX vs periop gem-based RT for (borderline) resectable PDAC in 375 patients. 21.9 vs 21.3 months HR 0.87 (0.68-1.12) Resection rate 77% vs 75% More details Sunday ESMO. Marc Besselink Eileen M O’Reilly Giovanni Marchegiani Flavio G Rocha, MD, FACS, FSSO Nigel B. Jamieson Arndt Vogel

Israel and Gaza: the killing of civilians must stop - The Lancet thelancet.com/journals/lance… Oslounivsykehus SoMe4HPB Prof Steve Wigmore Ernesto Sparrelid United Nations Espen Barth Eide Jonas Gahr Støre The Lancet Kjetil Tasken

Paranoid trener i dagens NRK på nett: "Fra 2013 til 2016 var Høgmo norsk landslagssjef, men mislykkes som flere av sine forfølgere og alle sine etterfølgere å ta Norge til mesterskap".

It’s time to find the third person for our international clinical and research HPB fellowship Karolinska-HPB starting September 2024! Please apply before December 15. Previous fellow Giampaolo Perri and current @TimTransplant have been excellent!

NORPACT-1 trial from 🇳🇴🇸🇪🇫🇮🇩🇰 out The Lancet Gastroenterology & Hepatology! Neoadjuvant FOLFIRINOX versus upfront surgery in resectable #pancreaticcancer, 140 pts Median survival: neoadjuvant 25mo, surgery 39mo (HR 1.52 [1.00-2.33]) ❌ No benefit from neoadjuvant! Free link: sciencedirect.com/science/articl…

NORPACT-1 published in The Lancet Gastroenterology & Hepatology. Phase-2 RCT. Neoadjuvant FOLFIRINOX vs upfront surgery in resectable pancreatic head cancer. Great team effort in 12 centers in the Nordic countries 🇳🇴🇸🇪🇩🇰🇫🇮 ✅Neoadjuvant FOLFIRINOX did not improve survival compared to upfront surgery

An honour and a pleasure to take part in final examination of HPB fellows Dr. Kirubel and Dr. Henock at St. Paul's in Addis Ababa. With consultant surgeons (fltr): Shanko, Gulilat, Henok, (Kirubel & Henock), KL, Wuletaw & Engida.

Exciting week and launch of a prospective registry for GI/HPB-resections at St. Paul’s in Addis. Core surgeon/anaest. collaborators and outstanding IT/registry jockeys Torkil Grindstein and Kevin Thon from Tromsø. ⁦SKDE_no⁩ ⁦@HelseNord⁩

A privilege to meet and discuss HPB surgery with the team at Ayder university hospital in Mekele, Tigray region. Warm thanks to dr. Reiye Isaias for hosting me and offering to do it again.

Thanks To Kristoffer Kim Dietrich and Lynn and anyone else involved in making an epic #NorthSeaHPB meeting in Tromsø

Blumgart lecture @ahpba #ahpba24 : Prof Olusegun gives an inspired and inspiring talk about building a HPB program in West Africa. What an effort!! @ihpba supporting this and other initiatives with #hpbridge program. Peter Kingham Sean Cleary Kristoffer Lassen

Together with Isaac Alatise (Ilè-Ifé, Nigeria) and the future of HPB surgery in Ethiopia (fltr): Gulilat Tigiye and Wuletaw Chane (both Paulos, Addis), (KL), Reiye Esayas (Mekelle), (IA), Joseph Solomon (Harrar), Andualam Dagne (Bahir Dar). #IHPBA2024

Surgery vs ablation for small-size CRC liver mtes at #ASCO24 🔎COLLISION phase III, 300 pts 👉medien size 14mm, 2mets 👉mOS: no difference 👉similar local control 👉reduced morbidity & mortality in ablation arm 🧐Ablation very valid option ESMO - Eur. Oncology ILCA EASLnews

Amazing results, game changing trial! Ablation can now safely enter the main stage! @retoba1 Martijn Meijerink Kristoffer Lassen But local recurrence after liver resection was 14%? What do we think, liver surgeons? @eahpba @ahpba @ihpba

Tumor debulking to first-line CTx for patients with multiorgan metastatic colorectal cancer #ASCO24 🔎ORCHESTRA phase III, 382 pts 👉10 yr accrual 👉mPFS: 10.4 vs 10.5 mo 👉mOS: 27.5 vs 30 mo, HR: 0.88 🧐Tumor debulking does not make sense ESMO - Eur. Oncology

“There is no limit to what can be accomplished if it doesn’t matter who gets the credit.” Amazing opening to #NIHRGSU24 by A. Ramos-De la Medina, MD, FACS - so inspiring!

Delighted to hear about Oslounivsykehus trials #cholangiocarcinoma #TESLA 🚙 #TOMCAT🐱 moving to the 🪡 at #NordicHPB 🇳🇴 🇸🇪 🇩🇰 🇫🇮 Kudos 👏🏽 to Sheraz Yaqub and Kristoffer Lassen Cholangiocarcinoma Foundation ENS-CCA AMMF IHPBA #transplantoncology #hopedealer #endcancer